CA2756249C - Muscle function enhancing peptide derived from s100 protein - Google Patents

Muscle function enhancing peptide derived from s100 protein Download PDF

Info

Publication number
CA2756249C
CA2756249C CA2756249A CA2756249A CA2756249C CA 2756249 C CA2756249 C CA 2756249C CA 2756249 A CA2756249 A CA 2756249A CA 2756249 A CA2756249 A CA 2756249A CA 2756249 C CA2756249 C CA 2756249C
Authority
CA
Canada
Prior art keywords
peptide
seq
amino acid
calcium
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2756249A
Other languages
English (en)
French (fr)
Other versions
CA2756249A1 (en
Inventor
Patrick Most
Mirko Voelkers
Hugo Katus
Andrew Remppis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universität Heidelberg
Original Assignee
Universität Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Heidelberg filed Critical Universität Heidelberg
Publication of CA2756249A1 publication Critical patent/CA2756249A1/en
Application granted granted Critical
Publication of CA2756249C publication Critical patent/CA2756249C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2756249A 2009-04-16 2010-04-16 Muscle function enhancing peptide derived from s100 protein Expired - Fee Related CA2756249C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16996209P 2009-04-16 2009-04-16
US61/169,962 2009-04-16
PCT/EP2010/002343 WO2010118878A1 (en) 2009-04-16 2010-04-16 Muscle function enhancing peptide

Publications (2)

Publication Number Publication Date
CA2756249A1 CA2756249A1 (en) 2010-10-21
CA2756249C true CA2756249C (en) 2020-08-18

Family

ID=42226606

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2756249A Expired - Fee Related CA2756249C (en) 2009-04-16 2010-04-16 Muscle function enhancing peptide derived from s100 protein

Country Status (7)

Country Link
US (1) US9428564B2 (enExample)
EP (1) EP2419119B1 (enExample)
JP (1) JP5847073B2 (enExample)
CN (1) CN102395377B (enExample)
CA (1) CA2756249C (enExample)
ES (1) ES2638043T3 (enExample)
WO (1) WO2010118878A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6068347B2 (ja) * 2010-10-20 2017-01-25 ルプレクト−カールズ−ウニベルシタット ハイデルベルク 筋機能を増強させる短ペプチド
EP3052118A1 (en) * 2013-10-01 2016-08-10 Ruprecht-Karls-Universität Heidelberg S100 based treatment of cardiac power failure
CN117589740B (zh) * 2024-01-04 2025-02-11 南京市产品质量监督检验院(南京市质量发展与先进技术应用研究院) 一种高通量快速检测和评估化合物骨骼肌毒性的方法
WO2026132516A1 (en) 2024-12-20 2026-06-25 Patrick Most S100a1 protein-derived peptide for use in treating cancer or in treating or preventing antineoplastic agent-mediated cytotoxicity, cancer therapy-related cardiac dysfunction or cancer therapy related heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553929B2 (en) * 1994-06-13 2009-06-30 Vanderbilt University Cell permeable peptides for inhibition of inflammatory reactions and methods of use
GB9614871D0 (en) * 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
DE19915485A1 (de) * 1999-04-07 2000-10-19 Hugo A Katus Therapie der Herzinsuffizienz

Also Published As

Publication number Publication date
US20120129758A1 (en) 2012-05-24
CN102395377B (zh) 2016-10-19
EP2419119A1 (en) 2012-02-22
JP5847073B2 (ja) 2016-01-20
CA2756249A1 (en) 2010-10-21
WO2010118878A1 (en) 2010-10-21
EP2419119B1 (en) 2017-06-07
CN102395377A (zh) 2012-03-28
ES2638043T3 (es) 2017-10-18
JP2012524034A (ja) 2012-10-11
US9428564B2 (en) 2016-08-30

Similar Documents

Publication Publication Date Title
Jiang et al. High-but not low-molecular weight FGF-2 causes cardiac hypertrophy in vivo; possible involvement of cardiotrophin-1
US20170119853A1 (en) Cardio-Metabolic and Vascular Effects of GLP-1 Metabolites
CN102333536B (zh) β-抑制蛋白效应器和组合物以及其应用方法
US9428564B2 (en) Muscle function enhancing peptide
Patel et al. Disruption of protein kinase A localization using a trans-activator of transcription (TAT)-conjugated A-kinase-anchoring peptide reduces cardiac function
CN110325201B (zh) ApoM-Fc融合蛋白、其与鞘氨醇1-磷酸(S1P)的复合物以及用于治疗血管和非血管疾病的方法
CA2814967C (en) Short peptides for enhancing muscle function
CA2987365A1 (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of mild cognitive impairment
WO2023083010A1 (zh) 人类受试者心肌病的治疗
US20060211606A1 (en) Peptides
US8927498B2 (en) Compositions and methods useful in enhancement of memory
HK1167331A (en) Muscle function enhancing peptide
HK1167331B (en) Muscle function enhancing peptide
JP2016534029A (ja) Ｓ１００に基づく心臓パワー不全の処置
Zheng et al. Evaluation of tyrosine kinase inhibitors loaded injectable hydrogels for improving connexin43 gap junction intercellular communication
JP2024041839A (ja) 対象における拡張機能障害を治療するための手段及び方法
AU2004240707A1 (en) Spheron components useful in determining compounds capable of treating symptoms of Alzheimer's Disease
EP2870171B1 (en) Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban
JP2013523768A (ja) Ｒｆアミド関連ペプチドおよびその方法
EP1868637A1 (en) Mechano growth factor peptides and their use
Norby et al. Insulin-Like Growth Factor I Attenuates Diabetes-Induced Cardiac Contractile Dysfunction in Ventricular Myocytes
Hassel Microprotein Regulation of Cardiac Calcium Cycling and Contractility
Stanczyk Characterisation of a novel interaction between the cardiac myosin binding protein-C and the ryanodine receptor/calcium release channel
WO2019051111A1 (en) Purified biglycan variants and methods of use thereof
Kranias Phospholamban: A Promising Therapeutic Target

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150414

MKLA Lapsed

Effective date: 20220419